Free Trial
NASDAQ:ZURA

Zura Bio (ZURA) Stock Price, News & Analysis

Zura Bio logo
$4.38
-0.02 (-0.45%)
(As of 11/1/2024 ET)

About Zura Bio Stock (NASDAQ:ZURA)

Key Stats

Today's Range
$4.26
$4.42
50-Day Range
$3.30
$4.92
52-Week Range
$2.00
$6.35
Volume
122,531 shs
Average Volume
324,716 shs
Market Capitalization
$294.37 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.33
Consensus Rating
Moderate Buy

Company Overview

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.

Zura Bio Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
52nd Percentile Overall Score

ZURA MarketRank™: 

Zura Bio scored higher than 52% of companies evaluated by MarketBeat, and ranked 571st out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Zura Bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Zura Bio has only been the subject of 3 research reports in the past 90 days.

  • Read more about Zura Bio's stock forecast and price target.
  • Earnings Growth

    Earnings for Zura Bio are expected to decrease in the coming year, from ($0.47) to ($0.80) per share.

  • Price to Book Value per Share Ratio

    Zura Bio has a P/B Ratio of 2.37. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Zura Bio's valuation and earnings.
  • Percentage of Shares Shorted

    4.45% of the float of Zura Bio has been sold short.
  • Short Interest Ratio / Days to Cover

    Zura Bio has a short interest ratio ("days to cover") of 4.3.
  • Change versus previous month

    Short interest in Zura Bio has recently increased by 1.08%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Zura Bio does not currently pay a dividend.

  • Dividend Growth

    Zura Bio does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    4.45% of the float of Zura Bio has been sold short.
  • Short Interest Ratio / Days to Cover

    Zura Bio has a short interest ratio ("days to cover") of 4.3.
  • Change versus previous month

    Short interest in Zura Bio has recently increased by 1.08%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Zura Bio has a news sentiment score of 0.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.43 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Zura Bio this week, compared to 1 article on an average week.
  • Search Interest

    Only 1 people have searched for ZURA on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Zura Bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $200,187.00 in company stock.

  • Percentage Held by Insiders

    22.10% of the stock of Zura Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    61.14% of the stock of Zura Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Zura Bio's insider trading history.
Receive ZURA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zura Bio and its competitors with MarketBeat's FREE daily newsletter.

ZURA Stock News Headlines

Reviewing CG Oncology (NASDAQ:CGON) & Zura Bio (NASDAQ:ZURA)
Sell NVDA Now?
Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's what that means for your money. Billionaire Wall Street investors are quietly offloading millions of shares. What do they know that you don't? It's arguably the most popular stock in the world. Now, one 50-year Wall Street legend says its day in the sun could finally be coming to an end. Last year, he warned of two stocks that went on to crash 60%.
Zura Bio (NASDAQ:ZURA) Rating Reiterated by HC Wainwright
See More Headlines

ZURA Stock Analysis - Frequently Asked Questions

Zura Bio's stock was trading at $4.67 at the start of the year. Since then, ZURA shares have decreased by 6.2% and is now trading at $4.38.
View the best growth stocks for 2024 here
.

Zura Bio Limited (NASDAQ:ZURA) posted its quarterly earnings results on Tuesday, August, 13th. The company reported ($0.17) earnings per share for the quarter, missing analysts' consensus estimates of ($0.15) by $0.02.

Zura Bio's top institutional investors include Palumbo Wealth Management LLC (0.06%) and SG Americas Securities LLC (0.03%). Insiders that own company stock include Someit Sidhu, Van Amstel Arnout Ploos, Michael Howell and Kiran Nistala.
View institutional ownership trends
.

Shares of ZURA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Zura Bio investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Walt Disney (DIS).

Company Calendar

Last Earnings
8/13/2024
Today
11/02/2024
Next Earnings (Estimated)
11/11/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ZURA
Web
N/A
Fax
N/A
Employees
3
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$17.33
High Stock Price Target
$26.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+295.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$-69,240,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.85 per share

Miscellaneous

Free Float
52,354,000
Market Cap
$294.37 million
Optionable
Optionable
Beta
0.16
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

This page (NASDAQ:ZURA) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners